title: Multi-drug resistant oral Candida species isolated from HIV-positive patients in South Africa and Cameroon.
abstract: Candida species are a common cause of infection in immune-compromised HIV-positive individuals, who are usually treated with the antifungal drug, fluconazole, in public hospitals in Africa. However, information about the prevalence of drug resistance to fluconazole and other antifungal agents on Candida species is very limited. This study examined 128 Candida isolates from South Africa and 126 Cameroonian Candida isolates for determination of species prevalence and antifungal drug susceptibility. The isolates were characterized by growth on chromogenic and selective media and by their susceptibility to 9 antifungal drugs tested using the TREK™ YeastOne9 drug panel (Thermo Scientific, USA). Eighty-three percent (82.8%) of South African isolates were Candida albicans (106 isolates), 9.4% were Candida glabrata (12 isolates), and 7.8% were Candida dubliniensis (10 isolates). Of the Cameroonian isolates, 73.02% were C. albicans (92 isolates); 19.05% C. glabrata (24 isolates); 3.2% Candida tropicalis (4 isolates); 2.4% Candida krusei (3 isolates); 1.59% either Candida kefyr, Candida parapsilopsis, or Candida lusitaneae (2 isolates); and 0.79% C. dubliniensis (1 isolate). Widespread C. albicans resistance to azoles was detected phenotypically in both populations. Differences in drug resistance were seen within C. glabrata found in both populations. Echinocandin drugs were more effective on isolates obtained from the Cameroon than in South Africa. A multiple-drug resistant C. dubliniensis strain isolated from the South African samples was inhibited only by 5-flucytosine in vitro on the YO9 panel. Drug resistance among oral Candida species is common among African HIV patients in these 2 countries. Regional surveillance of Candida species drug susceptibility should be undertaken to ensure effective treatment for HIV-positive patients.
authors.affiliation: Oral Microbiology Group, Department of Medical Biosciences, University of the Western Cape, Cape Town, South Africa.
authors.forename: Pedro Miguel
authors.initials: PM
authors.lastname: Dos Santos Abrantes
authors.affiliation: Department of Oral and Craniofacial Science, School of Dentistry, University of Missouri-Kansas City, Kansas City, USA.
authors.forename: Carole P
authors.initials: CP
authors.lastname: McArthur
authors.affiliation: Oral Microbiology Group, Department of Medical Biosciences, University of the Western Cape, Cape Town, South Africa. Electronic address: cafrica@uwc.ac.za.
authors.forename: Charlene Wilma Joyce
authors.initials: CW
authors.lastname: Africa
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology; D002163:Cameroon / Q000453:epidemiology; D002175:Candida / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification*; D002177:Candidiasis / Q000453:epidemiology / Q000382:microbiology*; D026141:Drug Resistance, Multiple, Fungal; D054714:Echinocandins / Q000494:pharmacology; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D015995:Prevalence; D013019:South Africa / Q000453:epidemiology
chemical_list: D000935:Antifungal Agents; D001393:Azoles; D054714:Echinocandins
keywords: Antifungal agents; Candida; Drug resistance; TREK